Waldron Private Wealth LLC Has $205,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Waldron Private Wealth LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 288 shares of the biopharmaceutical company’s stock after selling 78 shares during the period. Waldron Private Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $205,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of REGN. Rakuten Securities Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $37,000. Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Valley Wealth Managers Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on REGN shares. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $672.98 on Monday. The stock has a market cap of $73.95 billion, a P/E ratio of 16.65, a PEG ratio of 1.62 and a beta of 0.10. The company’s 50-day simple moving average is $720.81 and its 200 day simple moving average is $922.87. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.